In this role,
'This strategic appointment underscores our unwavering dedication to growth and innovation, and we are thrilled to have John join us at such an exciting time,' said Per Hellsund, President and CEO, Cybrexa. 'As we prepare for our next important milestones, we are confident John's insights and deep industry experience will propel the Company and the alphalex technology platform forward.'
'Cybrexa's innovative approach, leveraging pH in the tumor microenvironment to selectively kill cancer tissue while sparing healthy tissue, has the capability to revolutionize cancer treatment,' said Dr.
About CBX-12
CBX-12 is a clinical-stage, first-in-class peptide drug conjugate (PDC) that utilizes Cybrexa's proprietary alphalex technology to enhance delivery of exatecan to tumor cells and is composed of a pH-Low Insertion Peptide (pHLIP), a linker and exatecan. CBX-12 is designed to increase the efficacy and reduce the toxicity of topoisomerase I inhibition by delivering exatecan, a highly potent, second-generation topoisomerase I inhibitor, directly to the tumor cells. As an antigen-independent therapy, CBX-12 may have broad utility in patients who are not eligible for antigen-targeted therapies, including monoclonal antibodies and antibody-drug conjugates (ADCs), and has potential for use in combination regimens with other anti-cancer agents and immunotherapies. Data from the ongoing Phase 1 trial of CBX-12 in patients with metastatic solid tumors demonstrated preliminary anti-tumor activity in a heavily pretreated patient population with a favorable safety profile.
About the alphalex Technology Platform
The Cybrexa alphalex technology is a novel antigen-independent, peptide-drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pH-Low Insertion Peptides (pHLIPs) peptide, linker, and small molecule anti-cancer agent. pHLIP peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP was developed at
About Cybrexa
Cybrexa is a privately held clinical-stage biotechnology company pioneering novel antigen-independent tumor-targeting peptide drug conjugate (PDC) therapeutics. The company is led by a dynamic team of highly successful life science entrepreneurs and veteran drug development scientists. It is on a mission to create therapeutics that revolutionize the standard of care in oncology. Cybrexa's robust pipeline aims to combat breast cancer, ovarian cancer, non-small cell lung cancer, colorectal cancer and a range of other tumors. Its assets are built on Cybrexa's alphalex technology platform, which enables intracellular delivery of highly potent anticancer treatments. Cybrexa is based in
Contact:
Per Hellsund
Tel: 860-799-1517
Email: per.hellsund@cybrexa.com
Tel: 908-884-7024
Email: tara.dimilia@tmstrat.com
(C) 2024 Electronic News Publishing, source